Surrozen, Inc./DE — Investor Relations & Filings
Filings indexed
447
across all filing types
Latest filing
2026-05-14
Regulatory Filings
Country
US
United States of America
Listing
US
SRZN
Surrozen, Inc. is a clinical-stage company that discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is pioneering a new class of targeted regenerative antibodies designed to stimulate the body's own repair mechanisms. These therapeutics aim to repair a broad range of tissues and restore organs damaged by serious diseases and injuries, with the goal of unlocking the body's regenerative power.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-14 | English | |
| ARS - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | |
| DEF 14A - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | |
| 4 - Surrozen, Inc./DE (0001824893) (Issuer) | 2026-03-26 | English | |
| S-8 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | |
| S-3 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46301940 | 8-K | 2026-05-14 | English | ||
| 33150029 | ARS - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | ||
| 33149954 | DEF 14A - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | ||
| 33043640 | 4 - Surrozen, Inc./DE (0001824893) (Issuer) | 2026-03-26 | English | ||
| 33016647 | S-8 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 33016643 | S-3 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 33016227 | 8-K - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 31920802 | 4 Filing | 2026-02-18 | English | ||
| 31920788 | 4 Filing | 2026-02-18 | English | ||
| 31920763 | 4 Filing | 2026-02-18 | English | ||
| 31920810 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32899184 | 4 - SURROZEN, INC./DE (0001824893) (Filer) | 2026-02-13 | English | ||
| 31920907 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 31920877 | 4 Filing | 2026-02-03 | English | ||
| 31920884 | SCHEDULE 13G Filing | 2026-02-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
MAXCYTE, INC.
A cell-engineering company with a platform for developing c…
|
MXCT | US | Professional, scientific and te… |
|
Medicenna Therapeutics Corp.
A clinical-stage immunotherapy company developing novel eng…
|
MDNA | CA | Professional, scientific and te… |
|
Medicofarma Biotech Spolka Akcyjna
R&D company developing innovative medicines, medical device…
|
MDB | PL | Professional, scientific and te… |
|
Medigene AG
Develops TCR-guided immunotherapies for cancer; currently i…
|
MDG1 | DE | Professional, scientific and te… |
|
Medizen Humancare Inc Co., Ltd
A research company specializing in genomic analysis for per…
|
236340 | KR | Professional, scientific and te… |
|
Medpace Holdings, Inc.
A global CRO providing Phase I-IV clinical development for …
|
MEDP | US | Professional, scientific and te… |
|
MegaPro Biomedical Co. Ltd.
A clinical-stage biotech developing nanomedicines for oncol…
|
— | MY | Professional, scientific and te… |
|
MEMPHASYS LIMITED.
Develops cell separation solutions for human and animal rep…
|
MEM | AU | Professional, scientific and te… |
|
Metagenomi, Inc.
A genetic medicines company developing therapeutics with a …
|
MGX | US | Professional, scientific and te… |
|
MICROBA LIFE SCIENCES LIMITED
Analyzes gut microbiomes using metagenomic sequencing for t…
|
MAP | AU | Professional, scientific and te… |
Surrozen, Inc./DE via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34164/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34164 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34164 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34164 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34164}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Surrozen, Inc./DE (id: 34164)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.